{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:57:23Z","timestamp":1784793443409,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cmi.2022.11.026","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:52:15Z","timestamp":1669902735000},"page":"543.e1-543.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Increased reporting of venous and arterial thromboembolic events reported with tixagevimab\u2013cilgavimab for coronavirus disease 2019"],"prefix":"10.1016","volume":"29","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Flumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"de Canecaude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.11.026_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(22)00129-3","article-title":"Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study","volume":"22","author":"Sheward","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.11.026_bib3","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.11.026_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.11.026_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inform J"},{"key":"10.1016\/j.cmi.2022.11.026_bib6","first-page":"225","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Th\u00e9rapie."},{"key":"10.1016\/j.cmi.2022.11.026_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.11.026_bib8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.cgh.2020.07.050","article-title":"Hepatic disorders with the use of remdesivir for coronavirus 2019","volume":"18","author":"Montastruc","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2022.11.026_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.11.026_bib10","doi-asserted-by":"crossref","first-page":"o1009","DOI":"10.1136\/bmj.o1009","article-title":"Covid-19: has the spread of omicron BA.2 made antibody treatments redundant?","volume":"377","author":"Mahase","year":"2022","journal-title":"BMJ"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:35:53Z","timestamp":1761118553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22005997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1198743X22005997"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.11.026","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased reporting of venous and arterial thromboembolic events reported with tixagevimab\u2013cilgavimab for coronavirus disease 2019","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}